AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $1.67, $0.90 better than the analyst estimate of $0.77. Revenue for the quarter came in at $10.98 billion versus the consensus estimate of $10.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.